Molecular and Phenotypic Characterization of Nine Patients with STAT1 GOF Mutations in China

[1]  A. Bernasconi,et al.  Increased STAT1 Amounts Correlate with the Phospho-STAT1 Level in STAT1 Gain-of-function Defects , 2018, Journal of Clinical Immunology.

[2]  Jinqiao Sun,et al.  Reference values for peripheral blood lymphocyte subsets of healthy children in China. , 2018, The Journal of allergy and clinical immunology.

[3]  T. Kalina,et al.  Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation , 2018, Journal of Clinical Immunology.

[4]  Ivan K. Chinn,et al.  Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain‐of‐function mutations , 2017, The Journal of allergy and clinical immunology.

[5]  J. Casanova,et al.  STAT1 Gain-of-Function and Dominant Negative STAT3 Mutations Impair IL-17 and IL-22 Immunity Associated with CMC. , 2017, The Journal of investigative dermatology.

[6]  T. Morio,et al.  Hematopoietic stem cell transplantation in patients with gain‐of‐function signal transducer and activator of transcription 1 mutations , 2017, The Journal of allergy and clinical immunology.

[7]  R. Geha,et al.  Exaggerated follicular helper T‐cell responses in patients with LRBA deficiency caused by failure of CTLA4‐mediated regulation , 2017, The Journal of allergy and clinical immunology.

[8]  Yuan Zhang,et al.  PD-L1 up-regulation restrains Th17 cell differentiation in STAT3 loss- and STAT1 gain-of-function patients , 2017, The Journal of experimental medicine.

[9]  Y. Lau,et al.  Cellular and Molecular Defects Underlying Invasive Fungal Infections—Revelations from Endemic Mycoses , 2017, Front. Immunol..

[10]  Hao Wu,et al.  Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain‐of‐function mutation , 2017, The Journal of allergy and clinical immunology.

[11]  S. Fuchs,et al.  Common variable immunodeficiency, impaired neurological development and reduced numbers of T regulatory cells in a 10-year-old boy with a STAT1 gain-of-function mutation. , 2016, Gene.

[12]  M. Netea,et al.  Treatment options for chronic mucocutaneous candidiasis. , 2016, The Journal of infection.

[13]  T. Chatila,et al.  Severe Early-Onset Combined Immunodeficiency due to Heterozygous Gain-of-Function Mutations in STAT1 , 2016, Journal of Clinical Immunology.

[14]  J. Casanova,et al.  Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. , 2016, Blood.

[15]  T. Hijikata,et al.  Distal regulatory element of the STAT1 gene potentially mediates positive feedback control of STAT1 expression , 2016, Genes to cells : devoted to molecular & cellular mechanisms.

[16]  S. Smeekens,et al.  Gain‐of‐function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC) , 2015, European journal of immunology.

[17]  J. Casanova,et al.  Monogenic mutations differentially affect the quantity and quality of T follicular helper cells in patients with human primary immunodeficiencies. , 2015, The Journal of allergy and clinical immunology.

[18]  J. Franco,et al.  The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1 , 2015, Journal of Clinical Immunology.

[19]  T. Morio,et al.  Two Novel Gain-of-Function Mutations of STAT1 Responsible for Chronic Mucocutaneous Candidiasis Disease: Impaired Production of IL-17A and IL-22, and the Presence of Anti–IL-17F Autoantibody , 2014, The Journal of Immunology.

[20]  J. Casanova,et al.  Simple diagnosis of STAT1 gain‐of‐function alleles in patients with chronic mucocutaneous candidiasis , 2014, Journal of leukocyte biology.

[21]  S. Pereira,et al.  Fatal combined immunodeficiency associated with heterozygous mutation in STAT1. , 2014, The Journal of allergy and clinical immunology.

[22]  Y. Lau,et al.  Penicillium marneffei infection and impaired IFN-γ immunity in humans with autosomal-dominant gain-of-phosphorylation STAT1 mutations. , 2014, The Journal of allergy and clinical immunology.

[23]  S. Holland,et al.  Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. , 2013, The Journal of allergy and clinical immunology.

[24]  J. Yim,et al.  Immune deficiencies, infection, and systemic immune disordersDominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation–polyendocrinopathy–enteropathy–X-linked–like syndrome , 2013 .

[25]  J. Casanova,et al.  New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe , 2013, Journal of Medical Genetics.

[26]  R. Liu,et al.  A regulatory effect of IL-21 on T follicular helper-like cell and B cell in rheumatoid arthritis , 2012, Arthritis Research & Therapy.

[27]  Y. Hirose,et al.  Autosomal-Dominant Chronic Mucocutaneous Candidiasis with STAT1-Mutation can be Complicated with Chronic Active Hepatitis and Hypothyroidism , 2012, Journal of Clinical Immunology.

[28]  J. Craft.  Follicular helper T cells in immunity and systemic autoimmunity , 2012, Nature Reviews Rheumatology.

[29]  J. Casanova,et al.  Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes , 2012, Current Opinion in Immunology.

[30]  Huaxi Xu,et al.  Increased frequency of follicular helper T cells in patients with autoimmune thyroid disease. , 2012, The Journal of clinical endocrinology and metabolism.

[31]  A. Hoischen,et al.  STAT1 Hyperphosphorylation and Defective IL12R/IL23R Signaling Underlie Defective Immunity in Autosomal Dominant Chronic Mucocutaneous Candidiasis , 2011, PloS one.

[32]  A. Fischer,et al.  Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis , 2011, The Journal of experimental medicine.

[33]  A. Hoischen,et al.  STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. , 2011, The New England journal of medicine.

[34]  S. Simpson,et al.  Adaptive Avoidance of Reef Noise , 2011, PloS one.

[35]  S. Tangye,et al.  Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. , 2010, Arthritis and rheumatism.

[36]  T. Nomura,et al.  Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. , 2009, Immunity.

[37]  T. Wada,et al.  Analysis of T cell receptor Vβ diversity in peripheral CD4+ and CD8+ T lymphocytes in patients with autoimmune thyroid diseases , 2009, Clinical and experimental immunology.

[38]  F. Rieux-Laucat,et al.  Human TCR α/β+ CD4−CD8− Double-Negative T Cells in Patients with Autoimmune Lymphoproliferative Syndrome Express Restricted Vβ TCR Diversity and Are Clonally Related to CD8+ T Cells1 , 2008, The Journal of Immunology.

[39]  N. Takasu,et al.  Hashimoto’s thyroiditis: TGAb, TPOAb, TRAb and recovery from hypothyroidism , 2008, Expert review of clinical immunology.

[40]  Christine A. Biron,et al.  Type 1 Interferons and the Virus-Host Relationship: A Lesson in Détente , 2006, Science.

[41]  J. V. van Dongen,et al.  Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations. , 2001, Blood.